Tradition of Excellence
- New 56 bed HEPA-filtered Blood and Marrow Transplant, Leukemia, and Immunotherapy Unit
- HSC Processing Laboratory
- Onsite Flow Cytometry and Molecular Diagnostic Laboratories
- Radiation oncology department
- Dedicated HEPA air-filtered outpatient treatment center
- Extracorporeal Photopheresis (ECP) for the treatment of graft vs. host disease
- Onsite Blood Donation Facility- Atlanta Blood Services – ABS.com
Patients and families are at the center of our program. Each individual is treated with respect, dignity and compassion. We believe having the patient at the top of the treatment pyramid, enables Blood and Marrow Transplant Program at Northside Hospital (NH-BMT) team to deliver outstanding care and excellent patient satisfaction.
The Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP) has released the 2018 outcomes for blood and marrow transplants using related and unrelated donors. For ten consecutive years, 2009 – 2018, NH-BMT’s commitment to quality patient care has resulted in the Program achieving survival outcomes that significantly exceed the expected range in related and unrelated allogeneic donor transplants1. There were 177 adult and pediatric transplant centers included in the analysis2. Please visit bethematch.org/tcdirectory/index/60 to find additional information on understanding blood and marrow transplant survival outcome results.
Our program’s commitment to providing patients access to cutting edge clinical research trials is demonstrated by NH- BMT, one of twenty national BMT Programs and Program Consortia, to be selected as a Core Clinical Center for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
NH-BMT staff members include nationally recognized physicians, advanced practice providers, nurses, coordinators, clinical BMT PharmD’s, a dedicated health psychologist, nutritionists, social worker, physical therapists and ancillary specialists.
Types of Transplants Performed
The NH-BMT program is one of the largest clinical transplant programs in the United States, serving patients undergoing blood and marrow transplant , primary leukemia treatment and immunotherapy (CAR T cell).
- Our program does not employ interns, residents and physicians in fellowship training – Physician Bio’s.
- A BMTGA physician is on call 24 hours a day, 7 days a week.
- Call (404-255-1930) to refer/speak with a physician
The types of transplants performed are:
- Autologous Stem Cell Transplants
- Related and Unrelated Allogeneic Stem Cell Transplants
- Haploidentical Stem Cell Transplants
- Cord Blood Transplants
- Nonmyeloablative / Reduced Intensity Stem Cell Transplants
Comprehensive Inpatient and Outpatient Autologous and Allogeneic Transplant Program
We are committed to providing patients and their caregivers a comprehensive pathway to successful outcomes. While Northside has pioneered successful outpatient transplants, we are able to provide patients with the option to also have an inpatient autologous or allogeneic transplant.
At the New Patient Consult and Pre-BMT Evaluation, the NH-BMT team will meet with each patient and family member(s) to determine if an inpatient or outpatient transplant would be the best treatment/location option. We realize that for some patients, receiving an outpatient transplant is not feasible due to the lack of adequate care giver support, transportation, local housing requirements or financial considerations. The NH-BMT team works with each patient and their unique personal situation to determine the best location to have their transplant.
Nationally, NH-BMT has been a leader in the field of hematopoietic blood and marrow transplant by perfecting autologous and allogeneic transplants in the outpatient setting. BMTGA physician, Dr. Scott Solomon, wrote a peer reviewed article, Outpatient Myeloablative Allo-SCT: A comprehensive approach yields decrease hospital utilization and low TRM. Bone Marrow Transplantation 2010 March;45(3):468-75., which demonstrated that receiving mobilization of stem cells, high dose chemotherapy/total body irradiation and post-transplant follow-up care in the outpatient setting is safe with outstanding outcomes www.marrow.org and excellent patient satisfaction.
If you receive your transplant in the inpatient or outpatient setting, you will receive the same outstanding care from our dedicated NH-BMT Interdisciplinary Team.
1 For the tenth consecutive year (2009-18) NH-BMT achieved survival outcomes that significantly exceeded the expected range as reported in the Center for International Blood and Marrow Transplant Research Final 2018 Transplant Center Survival Report, December 10, 2018 and from reported outcome data from Be The Match®.
2 There were 177 adult and pediatric transplant centers included in the analysis. This survival information includes only patients who received their first allogeneic transplant between January 1, 2014 and December 31, 2016 using unrelated or related donors and who had reported follow-up. Specific transplant center information can be found at bethematch.org.